Health
FDA approves constipation drug
NEWS IN BRIEF — Posted Feb. 20, 2006
Amitiza, or lubiprostone, was approved by the Food and Drug Administration Jan. 31 for treating chronic constipation among adults for whom no known cause can be found. The product will be available as capsules to be taken twice a day with food.
Chronic idiopathic constipation is one of the most common disorders among Americans, according to the FDA. The condition affects more people older than 65 and women more often than men.
Amitiza works by increasing intestinal fluid secretion to help alleviate constipation. The most common adverse events reported included headache, nausea, diarrhea, abdominal pain and distension.
Three long-term studies showed that Amitiza decreased constipation severity, abdominal bloating and discomfort over six to 12 months of use.
It is recommended that physicians periodically assess the need for continued treatment.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2006/02/20/hlbf0220.htm.












